SCHEMBL6430583

SCHEMBL6430583

O=C(c1cc(Cl)nc2c1c(=O)ccn2-c1c(F)cccc1Nc1ccccc1)C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.33
MAPT P10636 2/20 0.33
WEE1 P30291 2/20 0.33
NPY5R Q15761 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
AURKA O14965 5/20 0.33
MAPK8 P45983 2/20 0.32
CDC7 O00311 1/20 0.32
ALK Q9UM73 1/20 0.32
GFER P55789 1/20 0.32
NGLY1 Q96IV0 1/20 0.32
USP2 O75604 1/20 0.31
HTT P42858 1/20 0.31
AURKB Q96GD4 1/20 0.31
CDK19 Q9BWU1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6430581 0.77 PDE11A (0.40) MAPTWEE1MEN1ALDH1A1RAB9A
SCHEMBL14215793 0.64 FABP4 (0.61) RXFP1MAPTMEN1ALDH1A1KMT2A
SCHEMBL6430582 0.61 ACP1 (0.40) MAPTMEN1MAPK1KMT2AMAPK8
SCHEMBL5871615 0.60 PDE11A (0.49) MAPTNPY5RMEN1ALDH1A1KMT2A
SCHEMBL14215835 0.59 MAPT (0.46) RXFP1MAPTMEN1KMT2AGFER
SCHEMBL23412937 0.58 DGAT1 (0.47) MAPTKDM4EMEN1ALDH1A1MAPK1
SCHEMBL30097592 0.58 DGAT1 (0.47) MAPTKDM4EMEN1ALDH1A1MAPK1
SCHEMBL5872038 0.58 PDE11A (0.66) MAPTWEE1MEN1ALDH1A1MAPK1
SCHEMBL14189060 0.58 GRIK1 (0.47) RXFP1MAPTMEN1ALDH1A1KMT2A
SCHEMBL8286065 0.58 PDE11A (0.46) KDM4EMEN1ALDH1A1KMT2AAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900205-B2 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders BAYER PHARMACEUTICALS CORPORATION (US) 2005-05-31 US disclosed